Corcept Therapeutics Incorporated filed a Form 8-K on November 3, 2026, disclosing its financial results for the quarter ended September 30, 2026, alongside a corporate update issued via press release.

Key Highlights

  • Filing date: November 3, 2026, the same date as the earliest event reported.
  • Reporting period: Quarter ended September 30, 2026.
  • Items invoked: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
  • Press release attached: Exhibit 99.1, a press release from Corcept Therapeutics Incorporated dated November 3, 2026, containing the financial results and corporate update.
  • Signing officer: Atabak Mokari, Chief Financial Officer, signed the report on behalf of the registrant.
  • Exchange listing: Common Stock ($0.001 par value) is listed on NASDAQ:CORT on the Nasdaq Capital Market.

Corcept Therapeutics Q3 2026 Earnings Disclosure via Form 8-K

Corcept Therapeutics Incorporated, a Delaware-incorporated company headquartered at 101 Redwood Shores Parkway, Redwood City, CA 94065, filed a current report with the U.S. Securities and Exchange Commission on November 3, 2026. According to the filing, the company issued a press release on that date announcing its financial results for the quarter ended September 30, 2026, as well as a corporate update. The press release is attached as Exhibit 99.1 and incorporated by reference into the filing.

The filing invokes two reporting items: Item 2.02, covering Results of Operations and Financial Condition, and Item 7.01, covering Regulation FD Disclosure. The filing notes that the information furnished under these items and in the attached press release "shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended." The filing further states the information is not incorporated by reference into any other regulatory filing unless specifically stated.

The report was signed by Atabak Mokari in his capacity as Chief Financial Officer. No financial figures from the quarterly results are reproduced within the body of the 8-K itself; the substantive financial disclosures are contained exclusively in Exhibit 99.1, the attached press release.

What Was Disclosed

Corcept Therapeutics filed a Form 8-K on November 3, 2026, to furnish its Q3 2026 earnings press release (Exhibit 99.1) under Items 2.02 and 7.01. The financial details of the quarter ended September 30, 2026, are contained in that exhibit.